RapidEye Swiss developer Numab Therapeutics announced Tuesday that Johnson & Johnson ( NYSE: JNJ ) has agreed to acquire its subsidiary Yellow Jersey Therapeutics, including its eczema candidate NM26, for $1.25B in cash. The bi-specific antibody is currently set to enter Phase 2 clinical development for the skin disorder atopic dermatitis, often called eczema.
Under the agreement, the New Brunswick, New Jersey-based pharma giant will obtain rights to develop, manufacture, and commercialize NM26 for atopic dermatitis and other targeted conditions. The transaction is expected to close in H2 2024. “We are thrilled to enter into this agreement with J&J and are confident they will be able to rapidly advance the development of NM26 for patients in need of a better treatment for atopic dermatitis and other conditions,” CEO of Numab David Urech remarked.
More on Johnson & Johnson Johnson & Johnson: Vital Signs Decent, A Compelling Value Case Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference (Transcript) ADHD diagnoses increasing, becoming an 'expanding public health concern': CDC J&J faces lawsuit over talc-related bankruptcy filings.
